Kanzawa Takao, Ito Hideaki, Kondo Yasuko, Kondo Seiji
J Biomed Biotechnol. 2003;2003(1):25-34. doi: 10.1155/S1110724303209013.
Malignant gliomas are the most common neoplasm in the central nervous system. When treated with conventional treatments including surgery, irradiation, and chemotherapy, the average life expectancy of the most malignant type, glioblastoma multiforme is usually less than 1 year. Therefore, gene therapy is expected to be an effective and possibly curative treatment. Many gene therapeutic approaches have demonstrated efficacy in experimental animal models. However, the current clinical trials are disappointing. This review focuses on current therapeutic genes/vectors/delivery systems/targeting strategies in order to introduce updated trends and hopefully indicate prospective gene therapy for malignant gliomas.
恶性胶质瘤是中枢神经系统中最常见的肿瘤。在接受包括手术、放疗和化疗在内的传统治疗时,最恶性的多形性胶质母细胞瘤的平均预期寿命通常不到1年。因此,基因治疗有望成为一种有效的、甚至可能治愈的治疗方法。许多基因治疗方法已在实验动物模型中显示出疗效。然而,目前的临床试验结果令人失望。本综述聚焦于当前的治疗基因/载体/递送系统/靶向策略,以介绍最新趋势,并有望为恶性胶质瘤指明前瞻性的基因治疗方向。